Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elias M. Bukundi"'
Autor:
Kissa W. Mwamwitwa PhD, Elias M. Bukundi Msc, Betty A. Maganda PhD, Castory Munishi MPhil, Adam M. Fimbo PhD, Deus Buma PhD, Eva P. Muro PhD, Wilber Sabiiti PhD, Danstan H. Shewiyo PhD, Morven C. Shearer PhD, Andrew D. Smith PhD, Eliangiringa A. Kaale PhD
Publikováno v:
Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 61 (2024)
The use of chiral medicines (possessing center(s) of asymmetric carbon) may cause adverse drug reactions (ADRs). The safety assurance of these medicines is critical. We aimed to evaluate registered and commonly used anti-infective chiral medicines ci
Externí odkaz:
https://doaj.org/article/f57cb79dcf0f4d78828dc7a9ca4fbbb3
Autor:
Kissa W. Mwamwitwa, Adam M. Fimbo, Elias M. Bukundi, Alex F. Nkayamba, Deus Buma, Eva P. Muro, Betty A. Maganda, Danstan H. Shewiyo, Morven C. Shearer, Andrew D. Smith, Eliangiringa A. Kaale
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Under-reporting of adverse drug events (ADEs) is a challenge facing developing countries including Tanzania. Given the high magnitude of under-reporting, it was necessary to develop and assess the effectiveness of a ‘structured stimulated
Externí odkaz:
https://doaj.org/article/7ae18a7b327747f6881673dacbf2a837
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 24, Iss , Pp 100263- (2021)
Introduction: Tuberculosis (TB) is the global leading cause of death from an infectious agent. Tanzania is among the 30 high TB burden countries with a mortality rate of 47 per 100,000 population and a case fatality of 4%. This study assessed mortali
Externí odkaz:
https://doaj.org/article/5e0577b4b3984ff49f67b1d8185888da
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 24, Iss, Pp 100263-(2021)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Highlights • The crude mortality rate was estimated at 6.31 per 1000 person-months (pm). • More than half of deaths occurred in the first two months of treatment. • Lower survival probabilities were observed among TB/HIV co-infected, older TB p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b26385159d09650fea1c1f39ee1b8966
https://doi.org/10.1016/j.jctube.2021.100263
https://doi.org/10.1016/j.jctube.2021.100263